Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.80%
$0.25
0% positive prob.
5-Day Prediction
-5.24%
$0.24
0% positive prob.
20-Day Prediction
-30.24%
$0.17
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | +0.80% | -5.24% | -30.24% | 100.0% | Pending |
| Q3 2026 | BUY | +4.60% | +44.18% | +42.40% | 100.0% | Pending |
| Q2 2026 | SELL | +0.80% | -5.24% | -30.24% | 100.0% | Pending |
| Q1 2026 | BUY | +4.87% | +65.85% | +53.99% | 100.0% | +0.00% |
| Q3 2025 | SELL | +2.88% | -3.90% | -37.66% | 100.0% | -1.59% |
SEC 8-K filings with transcript text
Oct 22, 2026 · 100% conf.
1D
+4.60%
$0.35
Act: +3.40%
5D
+44.18%
$0.49
20D
+42.40%
$0.48
2 cosm_ex991.htm
cosm_ex991.htm
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days
· Q4 2026 U.S. revenue: approximately $15 million expected, based on the Company’s current growth trajectory
· Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin
· Subscription revenue: approximately $11.5 million expected, from approximately $8.2 million in first orders and approximately $3.3 million in renewals
· Order volume: 14,624 online checkout orders tracked as of October 19, 2026, up 34% from the 10,881 announced on October 14, 2026
· Subscription growth: 8,940 active subscriptions as of October 19, 2026, up 42% from the 6,287 announced on October 14, 2026, with more than 40,000 expected by year-end
· Monthly subscription value: $1,325,338 at standard renewal pricing as of October 19, 2026, up 44% from $919,945 announced on October 14, 2026
CHICAGO, IL / ACCESS Newswire / October 19, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that, based on its current growth trajectory, it expects U.S. revenue of approximately $15 million for the fourth quarter of 2026, with gross profit of approximately $10.5 million. Subscriptions are expected to generate more than three-quarters of fourth quarter U.S. revenue, and momentum toward this outlook continues to build: as of October 19, 2026, active U.S. subscriptions reached 8,940, up 42% from the 6,287 announced on October 14, 2026.
Fourth Quarter 2026 U.S. Outlook
Based on its current growth trajectory, Cosmos Health expects its U.S. revenue for the fourth quarter ending December 31, 2026 to reach approximately $15 million, with gross profit of approximately $10.5 million. The outlook reflects the Company’s U.S. online direct-to-consumer business and is supported by a significantly expanded marketing budget for the fourth quarter.
Revenue is expected to accelerate through the quarter, with December expected to be the strongest month. New subscriptions and renewals are expected to build on each other month after month.
Revenue Analysis
Expected Q4 2026 U.S. results
Amount
First orders from new subscribers
~$8.2 million
Renewals of subscriptions started during the quarter
~$3.3 million
Total subscription revenue
~$11.5 million
One-time purchases
~$3.5 million
Total U.S. revenue
~$15.0 million
Subscriptions are expected to generate approximately $11.5 million, or more than three-quarters, of fourth quarter U.S. revenue. This includes approximately $8.2 million from first orders placed by new subscribers and approximately $3.3 million from renewals of subscriptions started during the quarter. One-time purchases are expected to contribute the remaining approximately $3.5 million.
Renewals are expected to grow each month as successive cohorts of subscribers renew, steadily increasing the recurring portion of U.S. revenue.
2
Gross Profit
At an expected gross margin of approximately 70%, the Company expects fourth quarter U.S. gross profit of approximately $10.5 million. The Company believes this margin profile reflects the efficiency of its direct-to-consumer model.
Key Growth Drivers and Expected Growth
The Company’s outlook is supported by several drivers: increased marketing investment in its U.S. direct-to-consumer platform, expanded digital customer acquisition, rising brand awareness, a broadening product offering, growing repeat purchases, and strong subscription adoption at checkout. Each new subscription adds to a recurring base, as subscribers renew month after month and average approximately 2.4 product units per subscription.
These drivers are already visible in recent results, and momentum is building further. As of October 19, 2026, the Company’s platform had tracked 14,624 U.S. online checkout orders, up 34% from the 10,881 announced on October 14, 2026, and the Company had 8,940 active U.S. subscriptions, up 42% from 6,287, with monthly subscription value at standard renewal pricing of $1,325,338, up 44% from $919,945 over the same five days. Overall, since the inception of the Company’s subscription platform, 65.2% of U.S. online checkout orders have included a subscription, up from 60.5% previously reported, rising to more than 85% of daily orders in recent days.
As a result, the Company expects U.S. daily sales to more than triple during the quarter, from $60,000 at its start to more than $200,000 by year-end, and expects active U.S. subscriptions to exceed 40,000 by year-end, more than four times current levels.
CEO Commentary
Greg Siokas, CEO of Cosmos Health, stated: “Our U.S. business has strong momentum entering the fourth quarter, and it is building further. In the five days sinc
Oct 9, 2026 · 100% conf.
1D
+4.60%
$0.35
Act: +3.40%
5D
+44.18%
$0.49
20D
+42.40%
$0.48
2 cosm_ex991.htm
cosm_ex991.htm
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
●
Record nine-month revenue of approximately $54.3 million — up 19%, or $8.7 million, from $45.6 million in the same period of 2025
●
Nine-month 2026 revenue nearly matches the whole of 2024 — when full-year revenue was $54.4 million — and represents 83% of record full-year 2025 revenue of $65.3 million
●
Record third-quarter revenue of approximately $17.4 million — exceeding the previous Q3 record of $17.1 million set in 2025, and up 40% on Q3 2024
●
Every quarter of 2026 has set a record for its period — Q1, Q2 and Q3 each exceeded the highest revenue previously reported for that quarter
●
Growth across all core segments — contract manufacturing, pharmaceutical distribution and proprietary brands, with accelerating sales momentum in the United States
●
2026 revenue outlook reaffirmed — the Company continues to expect full-year revenue to surpass $90 million, with the fourth quarter expected to be the strongest in its history
1
CHICAGO, IL / ACCESS Newswire / October 7, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced preliminary revenue of approximately $54.3 million for the nine months ended September 30, 2026 — a Company record and an increase of 19%, or $8.7 million, over the $45.6 million reported for the same period of 2025. Preliminary revenue for the third quarter was approximately $17.4 million, the highest third quarter in the Company’s history. The Company also reaffirmed its expectation that full-year 2026 revenue will surpass $90 million.
Nine Months That Nearly Equal a Full Year
In nine months, Cosmos Health has generated approximately the same revenue it reported for the whole of 2024, when full-year revenue was $54.4 million, and 83% of the record $65.3 million reported for the whole of 2025. Measured against the first nine months of 2024, revenue is up 35%.
Record Revenue in Every Quarter of 2026
First, second and third-quarter revenue each exceeded the highest revenue the Company had previously reported for that quarter. The third quarter was achieved against the most demanding comparison of the three.
Third-quarter revenue of approximately $17.4 million compares with $17.1 million in the third quarter of 2025 — which was, at the time, the highest quarterly revenue the Company had ever reported, and itself represented growth of 38%. Against that record base, third-quarter revenue increased again. Measured over two years, third-quarter revenue is up 40% from $12.4 million in the third quarter of 2024.
2
2024
2025
Third quarter
+2%
+40%
Nine months to September 30
+19%
+35%
Full year
Over $90M (outlook)
+38%
+65%
2026 third-quarter and nine-month figures are preliminary and unaudited. Full-year 2026 reflects the Company’s outlook, not results. Percentages are calculated on rounded figures.
Growth Across the Company’s Core Segments
The increase reflects growth across each of the Company’s core segments. Contract manufacturing at Cana Laboratories reached a record production pipeline of more than 32.7 million units, and pharmaceutical distribution at CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies that continues to expand. The Company’s proprietary brands — among others, Sky Premium Life, C-Scrub and C-Sept — grew in their established markets and entered new territories and channels globally, while sales momentum in the United States continued to build.
2026 Outlook Reaffirmed: Over $90 Million in Revenue
Cosmos Health reaffirms its previously announced expectation that revenue for full-year 2026 will surpass $90 million, which would represent growth of approximately 38% over 2025. The Company currently expects the fourth quarter of 2026 to be the strongest quarter in its history, supported by contract manufacturing orders, seasonal strength in distribution and accelerating sales in the United States.
Greg Siokas, CEO of Cosmos Health, stated: “In nine months we have delivered approximately what took us a full year in 2024. Revenue of approximately $54.3 million is 19% ahead of last year, and it comes after a record first quarter, a record second quarter and now a record third quarter — the third achieved against the most demanding comparison in the Company’s history.
“That growth is coming from every part of the business. Our contract manufacturing pipeline is at a record level, our distribution volumes are the highest we have recorded, and our proprietary brands are growing in their established markets while reaching new ones.
“The infrastr
Aug 20, 2026 · 100% conf.
1D
+0.80%
$0.21
Act: +4.19%
5D
-5.24%
$0.20
20D
-30.24%
$0.15
Transcript text not available. View on SEC.gov →
This page provides Cosmos Health Inc. (COSM) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on COSM's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.